incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Water and aqueous buffers | Near neutral pH |
| Storage temperature | Minus 20 to minus 80 C | Long-term, lyophilized |
| Analytical method | RP-HPLC | Purity assessment |
| Typical purity | Greater than 95 percent | Research-grade material |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Produced by Frances Berrigan, directed by Christopher Swayne, made by Cicada Films with the Discovery Channel 8 September The Big G, about gravity; Saturn's gravity destroyed its moons, to make its rings; Newton's laws unleashed the industrial revolution; geophysicist Victoria Lagenheim of the USGS, and gravimetry (gravity mapping); physicist Gabriel Luther; astrophysicist Robert Kirshner of the Harvard-Smithsonian Center for Astrophysics; Andrulla Blanchette; Apollo asteroid (35396) 1997 XF11 will approach the Earth on 26 October 2028 at 600,000 miles; reproductive biologist Lynn Maxey Wiley of UC Davis; neurologist Edward Good; neuroscientist Muriel Ross of NASA Ames; astrobiologist James Clifford of NASA Ames; Ralph Pelligra, chief medical officer at NASA Ames; astronauts Bernard A. Harris Jr. and David Wolf (astronaut); the ISS would be complete by 2004; astrophysicist Alex Filippenko at University of California, Berkeley; astrophysicist Saul Perlmutter at Lawrence Berkeley National Laboratory; astrophysicist Adam Riess of the High-Z Supernova Search Team, who found in 1998 that the universe rate of expansion is increasing, winning the 2011 Nobel Prize for Physics.
== Work == Ranganathan's special passion was reproducing natural biochemical processes in the laboratory. She created a protocol which achieved the autonomous reproduction of imidazole, an ingredient of histadine and histamine with pharmaceutical importance. She also developed a working simulation of the urea cycle. As her career developed, she became a specialist in designing proteins to hold a wide variety of different conformations and designing nanostructures using self-assembling peptides.
=== Interactions === It should not be used concomitantly with medications known to prolong the QTc interval (e.g., 5-HT3 antagonists, tricyclic antidepressants, citalopram, etc.) as this may lead to an increased risk of QTc interval prolongation. Neither should it be given concurrently with lithium (medication) as it may increase the risk of lithium toxicity and neuroleptic malignant syndrome. It should not be given concurrently with other antipsychotics due to the potential for this to increase the risk of side effects, especially neurological side effects such as neuroleptic malignant syndrome. It should be avoided in patients on CNS depressants such as opioids, alcohol and barbiturates.
Sources: en.wikipedia.org
=== Effects on nontarget species === Some insecticides kill or harm other creatures in addition to those they are intended to kill. For example, birds may be poisoned when they eat food that was recently sprayed with insecticides or when they mistake an insecticide granule on the ground for food and eat it. Sprayed insecticide may drift from the area to which it is applied and into wildlife areas, especially when it is sprayed aerially.
The secession of the Liberal Republican Union in March 1926, and the beginning of the Ditadura Nacional at the end of May of the same year, marked the end of the Nationalist Republican Party. In the early 1930s many former members of the PRN joined the National Union, ruling party of the Estado Novo.
== Further reading == Nagano N, Ota M, Nishikawa K (September 1999). "Strong hydrophobic nature of cysteine residues in proteins". FEBS Lett. 458 (1): 69–71. Bibcode:1999FEBSL.458...69N. doi:10.1016/S0014-5793(99)01122-9. PMID 10518936. S2CID 34980474.
==== Cuba ==== Cuba has contributed security and counterintelligence to Venezuela's Maduro since before the US military buildup; that support has expanded during the buildup to include more bodyguards, security and counterintelligence officers, who are considered less likely to rise against Maduro. The government of Cuba said 32 citizens were killed engaging in "direct combat" in Venezuela during the 3 January capture of Maduro.
Sources: en.wikipedia.org
=== Legal status === In April 2025, the European Medicines Agency (EMA) recommended the refusal of a marketing authorization for Winlevi, a medicine intended for treating acne vulgaris. The EMA noted that Winlevi is a new class of medicine that blocks receptors for androgens. However, there is a risk of the medicine suppressing the working of three organs: the hypothalamus and pituitary glands in the brain and adrenal glands. The suppression of these organs could lead to impaired growth and sexual maturation, which is a major concern in adolescents. Although the company presented data to show that the risk was low, the EMA considered that these data, as well as measures the company proposed to minimize the risk, were not sufficient to approve the medicine for people from 12 years of age to less than 18 years of age. In May 2025, Cassiopea requested a re-examination of the EMA's April 2025 opinion. In October 2025, EMA issued marketing authorization for Winlevi.
== Interactions == CYP3A4 inhibitors can increase exposure to suvorexant while CYP3A4 inducers can decrease exposure to suvorexant. Combination of suvorexant with the strong CYP3A4 inhibitor ketoconazole increased suvorexant overall exposure by 2.79-fold and peak levels by about 1.25-fold, combination with the moderate CYP3A4 inhibitor diltiazem increased suvorexant overall exposure by 2.05-fold and peak levels by about 1.25-fold, and combination with the strong CYP3A4 inducer rifampin decreased suvorexant overall exposure by 88% and peak levels by about 65%. The elimination half-life of suvorexant (about 12 hours for suvorexant alone) was increased to 19.4 hours with ketoconazole and to 16.1 hours with diltiazem while it was decreased to 7.7 hours with rifampin. Concomitant use of suvorexant with strong CYP3A4 inhibitors is not recommended, while lower doses of suvorexant are recommended with moderate CYP3A4 inhibitors (5 mg starting dose and 10 mg maximum dose generally). The substantial decrease in suvorexant exposure with strong CYP3A4 inducers may result in loss of effectiveness. Suvorexant does not appear to have been assessed in combination with moderate CYP3A4 inducers (e.g., modafinil).
After 1990s new memoirs and archival materials have opened up the study of espionage and intelligence during the Cold War. Scholars are reviewing how its origins, its course, and its outcome were shaped by the intelligence activities of the United States, the Soviet Union, and other key countries. Special attention is paid to how complex images of one's adversaries were shaped by secret intelligence that is now publicly known.
==== Catechol O-methyltransferase (COMT) inhibitors ==== Entacapone (Comtan) – catechol O-methyltransferase (COMT) inhibitor Opicapone (BIA 9-1067; BIA-91067; Ongentys; ONO-2370) – catechol O-methyltransferase (COMT) inhibitor [341] Tolcapone (RO-407592; Tasmar) – catechol O-methyltransferase (COMT) inhibitor [342]
Hormone receptor proteins bind to a hormone as a result of an accumulation of weak interactions. Because of the relatively large size of enzymes and receptors, the large amount of surface area provides the basis for these weak interactions to occur. This binding is actually highly specific because of the complementarity of these interactions between polar, non-polar, charged, neutral, hydrophilic, or hydrophobic residues. Upon binding, the receptor often undergoes a conformational change and may bind further, signaling ligands to activate a signaling pathway. Because of these highly specific and high affinity interactions between hormones and their receptors, very low concentrations of hormone can produce significant cellular response. Receptors can have various different structures depending on the function of the hormone and the structure of its ligand. Therefore, hormone binding to its receptor is a complex process that can be mediated by cooperative binding, reversible and irreversible interactions, and multiple binding sites.
Sources: en.wikipedia.org
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.
Repeated temperature cycling can promote aggregation and peptide degradation. Dividing material into single-use aliquots limits this risk.
Mass spectrometry is commonly used to confirm molecular mass and detect structural modifications. It is often paired with chromatographic purity assessment.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.